BACKGROUND: The aim of this study was to assess the quality of life of patients with oropharyngeal squamous cell carcinoma after transoral robotic surgery (TORS). METHODS: Short Form (SF)-8 and Performance Status Scale (PSS) questionnaires were completed prior to surgery, 6 and 12 months of follow-up. RESULTS: In all, 38 patients treated with TORS followed by adjuvant therapy as indicated were prospectively enrolled. For PSS Eating and Diet domains, significant decreases occurred at 6 months (p ≤ .001 and p ≤ .001, respectively) but not at 12 months. Significant declines in PSS Speech were seen at 6 and 12 months (p ≤ .001 and p ≤ .001). There were no significant declines in the SF-8 domains, except for Bodily Pain and Global Health (6 months). Significantly higher PSS Eating and Diet scores were seen at 6 months for TORS alone compared with TORS and chemoradiation. CONCLUSIONS: Combination TORS and adjuvant therapy caused a temporary decrease in several domains at 6 months, returning to baseline including swallowing function in all patients.
BACKGROUND: The aim of this study was to assess the quality of life of patients with oropharyngeal squamous cell carcinoma after transoral robotic surgery (TORS). METHODS: Short Form (SF)-8 and Performance Status Scale (PSS) questionnaires were completed prior to surgery, 6 and 12 months of follow-up. RESULTS: In all, 38 patients treated with TORS followed by adjuvant therapy as indicated were prospectively enrolled. For PSS Eating and Diet domains, significant decreases occurred at 6 months (p ≤ .001 and p ≤ .001, respectively) but not at 12 months. Significant declines in PSS Speech were seen at 6 and 12 months (p ≤ .001 and p ≤ .001). There were no significant declines in the SF-8 domains, except for Bodily Pain and Global Health (6 months). Significantly higher PSS Eating and Diet scores were seen at 6 months for TORS alone compared with TORS and chemoradiation. CONCLUSIONS: Combination TORS and adjuvant therapy caused a temporary decrease in several domains at 6 months, returning to baseline including swallowing function in all patients.
Authors: M Reuschenbach; S Wagner; N Würdemann; S J Sharma; E-S Prigge; M Sauer; A Wittig; C Wittekindt; M von Knebel Doeberitz; J P Klussmann Journal: HNO Date: 2016-07 Impact factor: 1.284
Authors: B Lallemant; S Moriniere; P Ceruse; M Lebalch; K Aubry; S Hans; G Dolivet; O Malard; Q Bonduelle; S Vergez Journal: Eur Arch Otorhinolaryngol Date: 2017-10-14 Impact factor: 2.503
Authors: Dana M Hartl; Daniel F Brasnu; Jatin P Shah; Michael L Hinni; Robert P Takes; Kerry D Olsen; Luiz P Kowalski; Juan P Rodrigo; Primož Strojan; Gregory T Wolf; Alessandra Rinaldo; Carlos Suárez; William M Mendenhall; Vinidh Paleri; Arlene A Forastiere; Jochen A Werner; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-01-03 Impact factor: 2.503
Authors: S N Rogers; R S Pinto; J Lancaster; F Bekiroglu; D Lowe; S Tandon; T M Jones Journal: Eur Arch Otorhinolaryngol Date: 2016-04-18 Impact factor: 2.503